<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40839264</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Catheter Ablation vs Drug Therapy in Patients With Atrial Fibrillation and Nonmodifiable Recurrence Risk Factors: A Secondary Analysis of the CABANA Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>e2528124</StartPage><MedlinePgn>e2528124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2528124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2025.28124</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Large-scale randomized studies evaluating the impact of catheter ablation on cardiovascular prognoses across different atrial fibrillation (AF) recurrence risk profiles are lacking.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To investigate the benefits of catheter ablation in patients with varying numbers of nonmodifiable recurrence risk factors (NMRRFs).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This study was a post hoc subanalysis of the multinational, multicenter, open-label Catheter Ablation vs Anti-Arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) randomized clinical trial, for which enrollment occurred from November 2009 to April 2016, with follow-up until December 31, 2017. Individuals with AF and at least 1 stroke risk factor were recruited in the CABANA trial. Only those with complete NMRRF data were included in this secondary analysis. Data were analyzed from November 1, 2023, to May 12, 2025.</AbstractText><AbstractText Label="EXPOSURE" NlmCategory="UNASSIGNED">Patients were categorized into 2 subgroups based on their number of NMRRFs (&lt;3 or &#x2265;3 risk factors).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary end point of the CABANA trial was death, disabling stroke, serious bleeding, or cardiac arrest. Four NMRRFs were examined: AF duration more than 1 year, persistent or long-standing persistent AF, age older than 65 years, and female sex. Multivariable Cox proportional hazards regression models with adjustment were performed to investigate the benefit of ablation in each subgroup.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, 2185 patients (median age, 67.0 years [IQR, 62.0-72.0 years]; 1373 males [62.8%]) with complete NMRRF data were included. Of these patients, 1100 (50.3%) were randomized to receive catheter ablation and 1085 (49.7%) were randomized to receive drug therapy. Most patients (1469 [67.2%]) had fewer than 3 NMRRFs, while 716 (32.8%) had 3 or more. In patients with fewer than 3 NMRRFs, catheter ablation reduced the primary end point (adjusted hazard ratio [AHR], 0.59 [95% CI, 0.41-0.86]). However, the difference was not significant in those with 3 or more NMRRFs (AHR, 1.55 [95% CI, 0.93-2.58]). The interaction between the primary end point and the NMRRF category was significant (P for interaction&#x2009;=&#x2009;.003). Across all NMRRF groups, ablation did not reduce all-cause mortality (&lt;3 NMRRFs: AHR, 0.65 [95% CI, 0.41-1.02] and &#x2265;3 NMRRFs: AHR, 1.23 [95% CI, 0.66-2.33]) but decreased AF recurrence (&lt;3 NMRRFs: AHR, 0.46 [95% CI, 0.40-0.52] and &#x2265;3 NMRRFs: AHR, 0.58 [95% CI, 0.49-0.69]) and improved quality of life throughout follow-up for symptom frequency (&lt;3 NMRRFs: -1.63 [95% CI, -2.18 to -1.07] and &#x2265;3 NMRRFs: -1.15 [95% CI, -1.98 to -0.31]).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this secondary analysis of the CABANA randomized clinical trial, the findings suggest that catheter ablation yielded significant cardiovascular benefits in patients with AF with fewer than 3 NMRRFs compared with drug therapy. This study lays the foundation for more personalized AF management, potentially optimizing resource allocation and influencing the direction of research and clinical practice in this field.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT00911508.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yanfang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Liu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sang</LastName><ForeName>Caihua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Jianzeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Changsheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Engineering Research Center of Medical Devices for Cardiovascular Diseases, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00911508</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1001/jamanetworkopen.2025.28136</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Dong reported receiving honoraria for presentations from Johnson &amp; Johnson outside the submitted work. Dr Ma reported receiving lecture fees and honoraria from Bristol Myers Squibb, Pfizer, Johnson &amp; Johnson, Boehringer-Ingelheim, and Bayer outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839264</ArticleId><ArticleId IdType="pmc">PMC12371518</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2025.28124</ArticleId><ArticleId IdType="pii">2837846</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Turagam MK, Musikantow D, Whang W, et al. Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation: a meta-analysis of randomized clinical trials. JAMA Cardiol. 2021;6(6):697-705. doi: 10.1001/jamacardio.2021.0852</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2021.0852</ArticleId><ArticleId IdType="pmc">PMC8082432</ArticleId><ArticleId IdType="pubmed">33909022</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont L, Bisbal F, Hern&#xe1;ndez-Madrid A, et al. ; SARA investigators . Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014;35(8):501-507. doi: 10.1093/eurheartj/eht457</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht457</ArticleId><ArticleId IdType="pmc">PMC3930872</ArticleId><ArticleId IdType="pubmed">24135832</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty S, Santangeli P, Mohanty P, et al. Catheter ablation of asymptomatic longstanding persistent atrial fibrillation: impact on quality of life, exercise performance, arrhythmia perception, and arrhythmia-free survival. J Cardiovasc Electrophysiol. 2014;25(10):1057-1064. doi: 10.1111/jce.12467</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.12467</ArticleId><ArticleId IdType="pubmed">24903064</ArticleId></ArticleIdList></Reference><Reference><Citation>Natale A, Calkins H, Osorio J, et al. ; PRECEPT Investigators . Positive clinical benefit on patient care, quality of life, and symptoms after contact force-guided radiofrequency ablation in persistent atrial fibrillation: analyses from the PRECEPT prospective multicenter study. Circ Arrhythm Electrophysiol. 2021;14(1):e008867. doi: 10.1161/CIRCEP.120.008867</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.120.008867</ArticleId><ArticleId IdType="pubmed">33290093</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SU, Rahman H, Talluri S, Kaluski E. The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: a systematic review and meta-analysis. JACC Clin Electrophysiol. 2018;4(5):626-635. doi: 10.1016/j.jacep.2018.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2018.03.003</ArticleId><ArticleId IdType="pubmed">29798790</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglar JA, Chung MK, Armbruster AL, et al. ; Peer Review Committee Members . 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001193</ArticleId><ArticleId IdType="pmc">PMC11095842</ArticleId><ArticleId IdType="pubmed">38033089</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Bai Y, Shantsila A, Fauchier L, Potpara TS, Lip GYH. Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review. Clin Res Cardiol. 2017;106(10):813-823. doi: 10.1007/s00392-017-1123-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-017-1123-0</ArticleId><ArticleId IdType="pmc">PMC5613037</ArticleId><ArticleId IdType="pubmed">28560516</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gelder IC, Rienstra M, Bunting KV, et al. ; ESC Scientific Document Group . 2024 ESC Guidelines for the Management of Atrial Fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae176</ArticleId><ArticleId IdType="pubmed">39210723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222-2231. doi: 10.1016/j.jacc.2014.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.09.028</ArticleId><ArticleId IdType="pubmed">25456757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024;26(4):1-107. doi: 10.1093/europace/euae043</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euae043</ArticleId><ArticleId IdType="pmc">PMC11000153</ArticleId><ArticleId IdType="pubmed">38587017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosich F, Schumacher K, Potpara T, Lip GY, Hindricks G, Kornej J. Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation. Clin Cardiol. 2019;42(2):320-329. doi: 10.1002/clc.23139</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.23139</ArticleId><ArticleId IdType="pmc">PMC6712319</ArticleId><ArticleId IdType="pubmed">30578568</ArticleId></ArticleIdList></Reference><Reference><Citation>Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). National Heart, Lung, and Blood Institute . Accessed October 6, 2023. https://biolincc.nhlbi.nih.gov/home/</Citation></Reference><Reference><Citation>Packer DL, Mark DB, Robb RA, et al. ; CABANA Investigators . Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261-1274. doi: 10.1001/jama.2019.0693</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.0693</ArticleId><ArticleId IdType="pmc">PMC6450284</ArticleId><ArticleId IdType="pubmed">30874766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark DB, Anstrom KJ, Sheng S, et al. ; CABANA Investigators . Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1275-1285. doi: 10.1001/jama.2019.0692</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.0692</ArticleId><ArticleId IdType="pmc">PMC6450275</ArticleId><ArticleId IdType="pubmed">30874716</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer DL, Mark DB, Robb RA, et al. ; CABANA Investigators . Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation (CABANA) trial: study rationale and design. Am Heart J. 2018;199:192-199. doi: 10.1016/j.ahj.2018.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2018.02.015</ArticleId><ArticleId IdType="pmc">PMC6517320</ArticleId><ArticleId IdType="pubmed">29754661</ArticleId></ArticleIdList></Reference><Reference><Citation>Berruezo A, Tamborero D, Mont L, et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J. 2007;28(7):836-841. doi: 10.1093/eurheartj/ehm027</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehm027</ArticleId><ArticleId IdType="pubmed">17395676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornej J, Hindricks G, Shoemaker MB, et al. The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. Clin Res Cardiol. 2015;104(10):871-876. doi: 10.1007/s00392-015-0856-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-015-0856-x</ArticleId><ArticleId IdType="pmc">PMC4726453</ArticleId><ArticleId IdType="pubmed">25876528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiuk J, Dinov B, Kornej J, et al. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. Heart Rhythm. 2015;12(11):2207-2212. doi: 10.1016/j.hrthm.2015.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2015.07.003</ArticleId><ArticleId IdType="pubmed">26144350</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesquita J, Ferreira AM, Cavaco D, et al. Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure&#x2014;ATLAS score. Europace. 2018;20(FI_3):f428-f435. doi: 10.1093/europace/eux265</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eux265</ArticleId><ArticleId IdType="pubmed">29016770</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkle RA, Jarman JW, Mead RH, et al. Predicting atrial fibrillation ablation outcome: the CAAP-AF score. Heart Rhythm. 2016;13(11):2119-2125. doi: 10.1016/j.hrthm.2016.07.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2016.07.018</ArticleId><ArticleId IdType="pubmed">27435586</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasitlumkum N, Tokavanich N, Trongtorsak A, et al. Catheter ablation for atrial fibrillation in the elderly &gt;75 years old: systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2022;33(7):1435-1449. doi: 10.1111/jce.15549</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.15549</ArticleId><ArticleId IdType="pubmed">35589557</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura I, Aikawa T, Yokoyama Y, Takagi H, Kuno T. Catheter ablation for atrial fibrillation in elderly patients: systematic review and a meta-analysis. Pacing Clin Electrophysiol. 2022;45(1):59-71. doi: 10.1111/pace.14413</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pace.14413</ArticleId><ArticleId IdType="pubmed">34816458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Lai Y, Wang Y, et al. Very-early symptomatic recurrence is associated with late recurrence after radiofrequency ablation of atrial fibrillation. Europace. 2023;25(7):1-11. doi: 10.1093/europace/euad189</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad189</ArticleId><ArticleId IdType="pmc">PMC10337823</ArticleId><ArticleId IdType="pubmed">37417712</ArticleId></ArticleIdList></Reference><Reference><Citation>Charitakis E, Dragioti E, Stratinaki M, et al. Predictors of recurrence after catheter ablation and electrical cardioversion of atrial fibrillation: an umbrella review of meta-analyses. Europace. 2023;25(1):40-48. doi: 10.1093/europace/euac143</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac143</ArticleId><ArticleId IdType="pmc">PMC10103559</ArticleId><ArticleId IdType="pubmed">36037026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1(3):139-152. doi: 10.1016/j.jacep.2015.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2015.04.004</ArticleId><ArticleId IdType="pubmed">29759357</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro F, Di Biase L, Trivedi C, et al. Impact of uncontrolled hypertension on atrial fibrillation ablation outcome. JACC Clin Electrophysiol. 2015;1(3):164-173. doi: 10.1016/j.jacep.2015.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2015.04.002</ArticleId><ArticleId IdType="pubmed">29759360</ArticleId></ArticleIdList></Reference><Reference><Citation>Creta A, Provid&#xea;ncia R, Adrag&#xe3;o P, et al. Impact of type-2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation (European observational multicentre study). Am J Cardiol. 2020;125(6):901-906. doi: 10.1016/j.amjcard.2019.12.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.12.037</ArticleId><ArticleId IdType="pubmed">31973808</ArticleId></ArticleIdList></Reference><Reference><Citation>Fein AS, Shvilkin A, Shah D, et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013;62(4):300-305. doi: 10.1016/j.jacc.2013.03.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2013.03.052</ArticleId><ArticleId IdType="pubmed">23623910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt TE, Traaen GM, Aaker&#xf8;y L, et al. Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial. Heart Rhythm. 2022;19(9):1433-1441. doi: 10.1016/j.hrthm.2022.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2022.06.016</ArticleId><ArticleId IdType="pubmed">35716856</ArticleId></ArticleIdList></Reference><Reference><Citation>Zylla MM, Leiner J, Rahm AK, et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2022;15(9):e009281. doi: 10.1161/CIRCHEARTFAILURE.121.009281</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.121.009281</ArticleId><ArticleId IdType="pubmed">36126143</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwennesen HT, Andrade JG, Wood KA, Piccini JP. Ablation to reduce atrial fibrillation burden and improve outcomes: <i>JACC</i> review topic of the week. J Am Coll Cardiol. 2023;82(10):1039-1050. doi: 10.1016/j.jacc.2023.06.029

</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.06.029</ArticleId><ArticleId IdType="pmc">PMC11103629</ArticleId><ArticleId IdType="pubmed">37648353</ArticleId></ArticleIdList></Reference><Reference><Citation>Brachmann J, Sohns C, Andresen D, et al. Atrial fibrillation burden and clinical outcomes in heart failure: the CASTLE-AF trial. JACC Clin Electrophysiol. 2021;7(5):594-603. doi: 10.1016/j.jacep.2020.11.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2020.11.021</ArticleId><ArticleId IdType="pubmed">33640355</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Zhang J, Zuo S, et al. Patterns of postablation recurrence and adverse cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2025;14(9):e038832. doi: 10.1161/JAHA.124.038832</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.124.038832</ArticleId><ArticleId IdType="pmc">PMC12184226</ArticleId><ArticleId IdType="pubmed">40247625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rillig A, Borof K, Breithardt G, et al. Early rhythm control in patients with atrial fibrillation and high comorbidity burden. Circulation. 2022;146(11):836-847. doi: 10.1161/CIRCULATIONAHA.122.060274</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.060274</ArticleId><ArticleId IdType="pubmed">35968706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof P, Camm AJ, Goette A, et al. ; EAST-AFNET 4 Trial Investigators . Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi: 10.1056/NEJMoa2019422</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2019422</ArticleId><ArticleId IdType="pubmed">32865375</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrouche NF, Brachmann J, Andresen D, et al. ; CASTLE-AF Investigators . Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-427. doi: 10.1056/NEJMoa1707855</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707855</ArticleId><ArticleId IdType="pubmed">29385358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohns C, Fox H, Marrouche NF, et al. ; CASTLE HTx Investigators . Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023;389(15):1380-1389. doi: 10.1056/NEJMoa2306037</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2306037</ArticleId><ArticleId IdType="pubmed">37634135</ArticleId></ArticleIdList></Reference><Reference><Citation>Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability. Eur Heart J. 2019;40(16):1257-1264. doi: 10.1093/eurheartj/ehz085</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz085</ArticleId><ArticleId IdType="pmc">PMC6475520</ArticleId><ArticleId IdType="pubmed">30875424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med. 2012;172(13):997-1004. doi: 10.1001/archinternmed.2012.2266</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2012.2266</ArticleId><ArticleId IdType="pubmed">22664954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang C, Liu Q, Lai Y, et al. ; PROMPT-AF investigators . Pulmonary vein isolation with optimized linear ablation vs pulmonary vein isolation alone for persistent AF: the PROMPT-AF randomized clinical trial. JAMA. 2025;333(5):381-389. doi: 10.1001/jama.2024.24438</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.24438</ArticleId><ArticleId IdType="pmc">PMC11574720</ArticleId><ArticleId IdType="pubmed">39556379</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>